These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31206613)

  • 1. N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease.
    Monti DA; Zabrecky G; Kremens D; Liang TW; Wintering NA; Bazzan AJ; Zhong L; Bowens BK; Chervoneva I; Intenzo C; Newberg AB
    Clin Pharmacol Ther; 2019 Oct; 106(4):884-890. PubMed ID: 31206613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data.
    Monti DA; Zabrecky G; Kremens D; Liang TW; Wintering NA; Cai J; Wei X; Bazzan AJ; Zhong L; Bowen B; Intenzo CM; Iacovitti L; Newberg AB
    PLoS One; 2016; 11(6):e0157602. PubMed ID: 27309537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson's disease.
    Jenkins PO; Roussakis AA; De Simoni S; Bourke N; Fleminger J; Cole J; Piccini P; Sharp D
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):631-637. PubMed ID: 32381639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. I-123 DaTscan SPECT Brain Imaging in Parkinsonian Syndromes: Utility of the Putamen-to-Caudate Ratio.
    Matesan M; Gaddikeri S; Longfellow K; Miyaoka R; Elojeimy S; Elman S; Hu SC; Minoshima S; Lewis D
    J Neuroimaging; 2018 Nov; 28(6):629-634. PubMed ID: 29905019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus.
    Vriend C; Raijmakers P; Veltman DJ; van Dijk KD; van der Werf YD; Foncke EM; Smit JH; Berendse HW; van den Heuvel OA
    J Neurol Neurosurg Psychiatry; 2014 Feb; 85(2):159-64. PubMed ID: 23813742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.
    Pagano G; Niccolini F; Wilson H; Yousaf T; Khan NL; Martino D; Plisson C; Gunn RN; Rabiner EA; Piccini P; Foltynie T; Politis M
    Mov Disord; 2019 Oct; 34(10):1505-1515. PubMed ID: 31158314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyposmia as a marker of (non-)motor disease severity in Parkinson's disease.
    Roos DS; Twisk JWR; Raijmakers PGHM; Doty RL; Berendse HW
    J Neural Transm (Vienna); 2019 Nov; 126(11):1471-1478. PubMed ID: 31515655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
    Song IU; Chung YA; Oh JK; Chung SW
    Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study.
    Liu SY; Wu JJ; Zhao J; Huang SF; Wang YX; Ge JJ; Wu P; Zuo CT; Ding ZT; Wang J
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1448-53. PubMed ID: 26559130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of autonomic symptoms with presynaptic striatal dopamine depletion in drug-naive Parkinson's disease: An analysis of the PPMI data.
    Kim R; Jun JS
    Auton Neurosci; 2019 Jan; 216():59-62. PubMed ID: 30236547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
    Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
    Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.
    Bergareche A; Rodríguez-Oroz MC; Estanga A; Gorostidi A; López de Munain A; Castillo-Triviño T; Ruiz-Martínez J; Mondragón E; Gaig C; Lomeña F; Sarasqueta C; Tolosa E; Martí-Massó JF
    Mov Disord; 2016 Mar; 31(3):335-43. PubMed ID: 26686514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic degeneration induces early posterior cortical thinning in Parkinson's disease.
    Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J
    Neurobiol Dis; 2019 Apr; 124():29-35. PubMed ID: 30408592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degenerative parkinsonism in patients with psychogenic parkinsonism: A dopamine transporter imaging study.
    Felicio AC; Godeiro-Junior C; Moriyama TS; Shih MC; Hoexter MQ; Borges V; Silva SM; Aguiar Pde C; Andrade LA; Bressan RA; Ferraz HB
    Clin Neurol Neurosurg; 2010 May; 112(4):282-5. PubMed ID: 20061077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress.
    Coles LD; Tuite PJ; Öz G; Mishra UR; Kartha RV; Sullivan KM; Cloyd JC; Terpstra M
    J Clin Pharmacol; 2018 Feb; 58(2):158-167. PubMed ID: 28940353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson's disease.
    Katz M; Won SJ; Park Y; Orr A; Jones DP; Swanson RA; Glass GA
    Parkinsonism Relat Disord; 2015 May; 21(5):500-3. PubMed ID: 25765302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease.
    Scherfler C; Seppi K; Mair KJ; Donnemiller E; Virgolini I; Wenning GK; Poewe W
    Brain; 2012 Nov; 135(Pt 11):3348-54. PubMed ID: 23043142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease.
    Smith KM; Xie SX; Weintraub D
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):864-70. PubMed ID: 26534930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.